Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Distinct immunocyte-promoting and adipocyte-generating stromal components coordinate adipose tissue immune and metabolic tenors.

Spallanzani RG., Zemmour D., Xiao T., Jayewickreme T., Li C., Bryce PJ.

Animal Study on Type 2 Diabetes, published in Sci Immunol (2019) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Sci Immunol (2019)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
31053654
PMCID
PMC6648660
DOI
10.1126/sciimmunol.aaw3658
Citations
200

Abstract (original English)

Regulatory T cells (T regs ) are key brakes on the visceral adipose tissue (VAT) inflammation that regulates local and systemic metabolic tenor. Breakdown of this regulation promotes type 2 diabetes. The cytokine IL-33 expands and sustains the unique T reg population residing within VAT. Here, relying on single-cell RNA sequencing, we identified the major IL-33 producers in VAT to be particular mesenchymal stromal cell subtypes, related to but distinct from adipocyte progenitor cells. We explored modulation of the VAT stromal cell landscape with physiologic variables such as age and sex, as well as its remodeling in pathogenic states like obesity. Last, we uncovered a VAT T reg :stromal cell negative regulatory loop that keeps the potent effect of IL-33 under rein.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AdipocytesAnimalsDiabetes Mellitus, Type 2InflammationInterleukin-33Intra-Abdominal FatMaleMesenchymal Stem CellsMiceMice, Inbred C57BL

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research